Arrowstreet Capital Limited Partnership Boosts Stake in Abbott Laboratories $ABT

Arrowstreet Capital Limited Partnership lifted its position in Abbott Laboratories (NYSE:ABT) by 217.0% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,522,222 shares of the healthcare product maker’s stock after purchasing an additional 3,780,402 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Abbott Laboratories were worth $566,967,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. Caxton Associates LLP purchased a new stake in Abbott Laboratories in the 1st quarter valued at $290,000. Dickmeyer Boyce Financial Management Inc. purchased a new position in Abbott Laboratories during the 1st quarter worth $829,000. Ascension Capital Advisors Inc. acquired a new position in Abbott Laboratories in the first quarter valued at $459,000. Forefront Analytics LLC raised its holdings in shares of Abbott Laboratories by 34.3% in the first quarter. Forefront Analytics LLC now owns 5,043 shares of the healthcare product maker’s stock valued at $518,000 after buying an additional 1,287 shares during the last quarter. Finally, B&D White Capital Company LLC purchased a new stake in shares of Abbott Laboratories in the first quarter valued at about $2,413,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. The Goldman Sachs Group lowered their price target on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a report on Wednesday, May 27th. Barclays decreased their price objective on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research report on Monday, April 20th. Bank of America lowered their target price on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. UBS Group cut their price target on Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating for the company in a research note on Monday, April 20th. Finally, Leerink Partners decreased their price target on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a report on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $118.61.

Insider Buying and Selling

In other Abbott Laboratories news, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Performance

ABT opened at $100.87 on Friday. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The stock has a market cap of $175.70 billion, a P/E ratio of 32.64, a P/E/G ratio of 1.95 and a beta of 0.61. The stock’s 50 day simple moving average is $91.24 and its 200 day simple moving average is $101.32. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.51 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.Abbott Laboratories’s revenue was up 13.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts anticipate that Abbott Laboratories will post 5.51 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. Abbott Laboratories’s payout ratio is currently 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.